

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope, addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico
Type or print name


Signature

3-16-06
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

NADLER ET AL.

APPLICATION NO: 10/755,889

FILED: JANUARY 13, 2004

FOR: POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH
THE NF-KB PATHWAY

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references were cited in a search report in a corresponding European application. Copies of these references and the search report are enclosed herewith.

Also, copies of the other cited references are enclosed herewith.

In accordance with 37 C.F.R. §1.98(a)(2)(iii), applicants wish to call the Examiner's attention to related application U.S. Serial No. 10/308,279, filed December 3, 2002.


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned agent, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652


Date: 3-16-06

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
D0284 NP
APPLICATION NO.
10/755,889
APPLICANT
NADLER ET AL.
FILING DATE
JANUARY 13, 2004

Group

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. RELATED PATENT APPLICATIONS

EXAMINER INITIAL		U.S. APPLICATION	DATE OF FILING	NAME	CLASS	SUBCLASS	FILING DATE
	AA	10/308,279	12/3/02	Carman, et al.			

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AP	Ahmad, et al., "Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain", Molec. Cell, Vol. 12, pp. 1551-1564 (2003)
	AQ	Albagli-Curiel, et al., "Ambivalent role of BCL6 in cell survival and transformation", Oncogene, Vol. 22, pp. 507-516(2003)
	AR	Arima, et al., "A Putative Silencer Element in the IL-5 Gene Recognized by Bc16", J. Immunol., Vol. 169, pp. 829-836 (2002)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0284 NP
APPLICATION NO.
10/755,889
APPLICANT
NADLER ET AL.
FILING DATE
JANUARY 13, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Baron, et al., "The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: Implications for a role of BCL6 in the down-regulation of apoptosis", PNAS, Vol. 99(5), pp. 2860-2865 (2002)
2AB	Bellido, et al., "Bcl-6 and p53 mutations in lymphomas carrying the bcl-2/jh rearrangement", Haematologica, Vol. 87, pp. 908-917 (2002)
2AC	Bos, et al., "Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D ₁ and hypoxia-inducible factor-1 α (HIF-1 α)", Oncogene, Vol. 22, pp. 8948-8951 (2003)
2AD	Brown, et al., "Control of I κ B- α Proteolysis by Site-Specific, Signal-Induced Phosphorylation", Science, Vol. 267, pp. 1485-1488 (1995)
2AE	Burke, et al., "BMS-345541 Is a Highly Selective Inhibitor of I κ B Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF- κ B-dependent Transcription in Mice", J. Biol. Chem., Vol. 278(3), pp. 1450-1456 (2003)
2AF	Cattoretti, et al., "BCL-6 Protein Is Expressed in Germinal-Center B Cells", Blood, Vol. 86(1), pp. 45-53 (1995)
2AG	Chang, et. al., "Express on of p53, c-Myc, or Bcl-6 Suggests a Poor Prognosis in Primary Central Nervous System Diffuse Large B-Cell Lymphoma Among Immunocompetent Individuals", Arch. Pathol. Lab. Med., Vol. 127, pp. 208-212 (2003)
2AH	Chang, et al., "BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor", PNAS, Vol. 93, pp. 6947-6952 (1996)
2AI	Davies, et al., "Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene", Oncogene, Vol. 18, pp. 365-375 (1999)
2AJ	Mattos, et al., "FoxO3a and BCR-ABL Regulate <i>cyclin</i> D2 Transcription through a STAT5/BCL6-Dependent Mechanism", Molec. Cell. Biol., Vol. 24(22), pp. 10058-10071 (2004)
2AK	Dent, et al., "Control of Inflammation, Cytokine Expression, and Germinal Center Formation by BCL-6", Science, Vol. 276, pp. 589-592 (1997)
2AL	Deregibus, et al., "HIV-1-Tat Protein Activates Phosphatidylinositol 3-Kinase/AKT-dependent Survival Pathways in Kaposi's Sarcoma Cells", J. Biol. Chem., Vol. 277(28), pp. 25195-25202 (2002)
2AM	Dhordain, et al., "Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein", PNAS, Vol. 94, pp. 10762-10767 (1997)
2AN	Flenghi, et al., "A Specific Monoclonal Antibody (PG-B6) Detects Expression of the BCL-6 Protein in Germinal Center B Cells", Amer. J. Pathol., Vol. 147(2), pp. 405-411 (1995)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0284 NP
APPLICATION NO.
10/755,889
APPLICANT
NADLER ET AL.
FILING DATE
JANUARY 13, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	Gupta, et al., "Lineage-specific Modulation of Interleukin 4 Signaling by Interferon Regulatory Factor 4", J. Exp. Med., Vol. 190(12), pp. 1837-1848 (1999)
3AB	Hallermann, et al., "Molecular Cytogenetic Analysis of Chromosomal Breakpoints in the IGH, MYC, BCL6, and MALT1 Gene Loci in Primary Cutaneous B-cell Lymphomas", J. Invest. Dermatol., Vol. 123, pp. 213-219 (2004)
3AC	Hiscott, et al., "Hostile takeovers: viral appropriation of the NF- κ B pathway", J. Clin. Invest., Vol. 107(2), pp. 143-151 (2001)
3AD	Hofmann, et al., "The Promoter Context Determines Mutual Repression or Synergism between NF- κ B and the Glucocorticoid Receptor", Biol. Chem., Vol. 383, pp. 1947-1951 (2002)
3AE	Holton, et al., "A simple and efficient method for direct cloning of PCR products using ddT-tailed vectors", Nucleic Acids Res., Vol. 19(5), pp. 1156 (1990)
3AF	Johnson, et al., "A Simple, Rapid Technique for Precise Mapping of Multiple Sequences in Two Colors Using a Single Optical Filter Set", GATA, Vol. 8(2), pp. 75-76 (1991)
3AG	Huynh, et al., "BC0R, a novel corepressor involved in BCL-6 repression", Genes Devel., Vol. 14, pp. 1810-1823 (2000)
3AH	Jardin, et al., "Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3:14)(q27;q32) non-Hodgkin B-cell lymphoma", Blood, Vol. 102, pp. 1872-1876 (2003)
3AI	Jardin, et al., "Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma", Leukemia, Vol. 19, pp. 1824-1830 (2005)
3AJ	Johnson, et al., "A Simple, Rapid Technique for Precise Mapping of Multiple Sequences in Two Colors Using a Single Optical Filter Set", GATA, Vol. 8(2), pp. 75-76 (1991)
3AK	Johnson, et al., "Molecular Cloning of a Novel Human cdc2/CDC28-like Protein Kinase", J. Biol. Chem., Vol. 266(6), pp. 3402-3407 (1991)
3AL	Kanazawa, et al., "Expression of bcl-6 protein in normal skin and epidermal neoplasms", Path. Internat., Vol. 47, pp. 600-607 (1997)
3AM	Katzenberger, et al., "Cytogenetic Alterations Affecting BCL6 Are Predominantly Found in Follicular Lymphomas Grade 3B with a Diffuse Large B-Cell Component", Amer. J. Pathol., Vol. 165(2), pp. 481-490 (2004)
3AN	Kerchaert, et al., "LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas", Nature Genetics, Vol. 5, pp. 66-70 (1993)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0284 NP
APPLICATION NO.
10/755,889
APPLICANT
NADLER ET AL.
FILING DATE
JANUARY 13, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

4AA	Kurosu, et al., "BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells", <i>Oncogene</i> , Vol. 22, pp. 4459-4468 (2003)
4AB	Lee, et al., "POZ Domain Transcription Factor, FBI-1, Represses Transcription of ADH5/FDH by Interacting with the Zinc Finger and Interfering with DNA Binding Activity of SPI", <i>J. Biol. Chem.</i> , Vol. 277(30), pp. 26761-26768 (2002)
4AC	Lemercier, et al., "Class II Histone Deacetylases Are Directly Recruited by BCL6 Transcriptional Repressor", <i>J. Biol. Chem.</i> , Vol. 277(24), pp. 22045-22052 (2002)
4AD	Li, et al., "BCL-6 Negatively Regulates Expression of the NF- κ B p105/p50 Subunit", <i>J. Immunol.</i> , Vol. 174, pp. 205-214 (2005)
4AE	Lin, et al., "The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium", <i>Urol. Res.</i> , Vol. 31, pp. 272-275 (2003)
4AF	Lossos, et al., "The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene", <i>Leukemia</i> , Vol. 17, pp. 1390-1397 (2003)
4AG	Migliazza, et al., "Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma", <i>PNAS</i> , Vol. 92, pp. 12520-12524 (1995)
4AH	Miki, et al., "Molecular Cloning of the Breakpoint for 3q27 Translocation in B-Cell Lymphomas and Leukemias", <i>Blood</i> , Vol. 83(1), pp. 217-222 (1994)
4AI	Miki, et al., "Gene Involved in the 3q27 Translocation Associated With B-Cell Lymphoma, BCL5, Encodes a Krüppel-Like Zinc-Finger Protein", <i>Blood</i> , Vol. 83(1), pp. 26-32 (1994)
4AJ	Min, et al., "Point mutation of 5' noncoding region of BCL-6 gene in primary gastric lymphomas", <i>World J. Gastroenterol.</i> , Vol. 11(1), pp. 51-55 (2005)
4AK	Montesinos-Rongen, et al., "Molecular Characterization of BCL6 Breakpoints in Primary Diffuse Large B-cell Lymphomas of the Central Nervous System Identifies GAPD as Novel Translocation Partner", <i>Brain Pathol.</i> , Vol. 13, pp. 534-538 (2003)
4AL	Niu, Huifeng, "The Proto-Oncogene BCL-6 In Normal And Malignant B Cell Development", <i>Hematology Oncology</i> , Vol. 20, pp. 155-166 (2002)
4AM	Niu, et al., "BCL6 Controls the Expression of the B7-1/CD80 Costimulatory Receptor in Germinal Center B Cells", <i>J. Exp. Med.</i> , Vol. 198(2), pp. 211-221 (2003)
4AN	Ohno, H., "Pathogenetic role of BCL6 translocation in B-cell non-Hodgkin's lymphoma", <i>Histol Histopathol.</i> , Vol. 19, pp. 637-650 (2004)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0284 NP
APPLICATION NO.
10/755,889
APPLICANT
NADLER ET AL.
FILING DATE
JANUARY 13, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

5AA	Onizuka, et al., "BCL-6 Gene Product, a 92- to 98-kD Nuclear Phosphoprotein, Is Highly Expressed in Germinal Center B Cells and Their Neoplastic Counterparts", Blood, Vol. 86(1), pp. 28-37 (1995)
5AB	Pasqualucci, et al., "Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6", Leukemia Lymphoma, Vol. 44, Suppl. 3, pp. S5-S12 (2003)
5AC	Pasqualucci, et al., "Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma", Blood, Vol. 101(8), pp. 2914-2923 (2003)
5AD	Petrie, et al., "The Histone Deacetylase 9 Gene Encodes Multiple Protein Isoforms", J. Biol. Chem., Vol. 278(18), pp. 16059-16072 (2003)
5AE	Phan, et al., "The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells", Nature, Vol. 432, pp. 635-639 (2004)
5AF	Pileri, et al., "High Frequency of BCL-6 Mutations and Consistent Expression of the Transcription Factors OCT-2, BOB. 1, and PU.1 in the Absence of Immunoglobulins", Amer. J. Path., Vol. 162(1), pp. 243-253 (2003)
5AG	Pittaluga, et al., "BCL-6 Expression in Reactive Lymphoid Tissue and in B-Cell Non-Hodgkins Lymphomas", J. Pathol., Vol. 179, pp. 145-150 (1996)
5AH	Rack, et al., "Translocation of BCL2 and BCL6 to the same immunoglobulin heavy chain locus in a case of Follicular Lymphoma", Leuk. Lymphoma, Vol. 46(10), pp. 1513-1516 (2005)
5AI	Reichardt, et al., "Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor", EMBO J., Vol. 20(24), pp. 7168-7123 (2001)
5AJ	Roumier, et al., "FISH analysis with a YAC probe improves detection of LAZ3/BCL6 rearrangement in non-Hodgkin's lymphoma", Hematol. J., Vol. 1, pp. 117-125 (2000)
5AK	Shen, et al., "Mutation of BCL-6 Gene in Normal B Cells by the Process of Somatic Hypermutation of Ig Genes", Science, Vol. 280, pp. 1750-1752 (1998)
5AL	Shvarts, et al., "A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19 ^{ARF} -p53 signaling", Genes Develop., Vol. 16, pp. 681-686 (2002)
5AM	Sidransky, et al., "Identification of p53 Gene Mutations in Bladder Cancers and Urine Samples", Science, Vol. 252, pp. 706-709 (1991)
5AN	Tokuhiisa, Takeshi, "A role for Bcl6 in immune memory development", Vol. 47(16), pp. 2306-2312 (2002)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0284 NP
APPLICATION NO.
10/755,889
APPLICANT
NADLER ET AL.
FILING DATE
JANUARY 13, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

6AA	Ueda, et al., "Non-immunoglobulin/BCL6 Gene Fusion in Diffuse Large B-cell Lymphoma: Prognostic Implications", Leukemia Lymphoma, Vol. 43(7), pp. 1375-1381 (2002)
6AB	Vasanwala, et al., "Repression of AP-1 Function: A Mechanism for the Regulation of Blimp-1 Expression and B Lymphocyte Differentiation by the B Cell Lymphoma-6 Protooncogene", J. Immunol., Vol. 169, pp. 1922-1929 (2002)
6AC	Wang, et al., "Stat1 as a Component of Tumor Necrosis Factor Alpha Receptor 1-TRADD Signaling Complex to Inhibit NF- κ B Activation", Molec. Cell. Biol., Vol. 20(13), pp. 4505-4512 (2000)
6AD	Wlodarska, et al., "Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma", Blood, Vol. 101(2), pp. 706-710 (2003)
6AE	Wong, et al., "Components of the SMRT Corepressor Complex Exhibit Distinctive Interactions with the POZ Domain Oncoproteins PLZF, PLZF-RAR α , and BCL-6", J. Biol. Chem., Vol. 273(42), pp. 27695-27702 (1998)
6AF	Ye, et al., "The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation", Nature Genetics, Vol. 16, pp. 161-170 (1997)
6AG	Ye, et al., "Alterations of a Zinc Finger-Encoding Gene, BCL-6, in Diffuse Large-Cell Lymphoma", Science, Vol. 262, pp. 747-750 (1993)
6AH	Zhang, et al., "A Putative Exonic Splicing Polymorphism in the BCL6 Gene and the Risk of Non-Hodgkin Lymphoma", J. National Cancer Institute, Vol. 97(21), pp. 1616-1618 (2005)
6AI	Zhou, et al., "Transcriptional Regulation of the BCL-6 Gene: Mechanistic Dissection Using Mutant Cell Lines", Molec. Medicine, Vol. 8(10), pp. 645-654 (2002)
6AJ	NCBI Entrez Accession No. AB018337 (gi:3882308), Nagase, et al., June 16, 1999
6AK	NCBI Entrez Accession No. AB056421 (gi:13358931), Osada, et al., March 1, 2005
6AL	NCBI Entrez Accession No. L29219 (gi:632963), Johnson, et al., January 24, 1995
6AM	NCBI Entrez Accession No. NM_001706 (gi:21040323), Zhang, et al., December 4, 2005
6AN	NCBI Entrez Accession No. NM_005500 (gi:4885584), Lois, et al., October 16, 2005

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0284 NP
APPLICATION NO.
10/755,889
APPLICANT
NADLER ET AL.
FILING DATE
JANUARY 13, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

7AA	NCBI Entrez Accession No. NM_016323 (gi:7705930), Hochrainer, et al., October 23, 2005
7AB	NCBI Entrez Accession No. NM_022136 (gi:48762708), Zhu, et al., October 18, 2005
7AC	NCBI Entrez Accession No. NM_145169 (gi:21553316), Director MGC Project., September 24, 2005
7AD	
7AE	
7AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.